Kyle Bass Group Gets 1st Win As PTAB Nixes Gattex Claims

Law360, New York (October 24, 2016, 10:08 PM EDT) -- An organization started by hedge fund manager Kyle Bass to challenge drug patents notched its first victory Friday as the Patent Trial and Appeal Board found that the group had shown that most claims of a patent on Shire PLC's short bowel syndrome drug Gattex are invalid.

In a pair of final written decisions in America Invents Act inter partes reviews, the PTAB found that 61 of the 75 claims of the patent are invalid as obvious, as Bass' group, the Coalition for Affordable Drugs, argued...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.